Search

A recent study conducted by researchers at Aristotle University of Thessaloniki in Greece examined the immunogenicity of respiratory syncytial virus (RSV) vaccines in individuals over the age of 50. Immunosenescence, age-related changes in the immune system, can impact the effectiveness of vaccines in older adults. The study reviewed clinical trials of RSV vaccines in this age group and found that the vaccines demonstrated efficacy and generated immune responses similar to those seen in younger adults. The research highlights the importance of understanding immunosenescence and its impact on vaccination in older adults. [Extracted from the article]

A new report discusses research findings on influenza vaccines conducted by Sinovac Biotech Co. Ltd. The study aimed to evaluate the non-inferiority of Sinovac's quadrivalent influenza vaccine (QIV) compared to a comparator QIV in a population aged 3 years and older in Chile and the Philippines. The phase 3 clinical trial found that Sinovac QIV induced non-inferior immune responses to all four strains and had slightly higher geometric mean titers (GMTs) than the comparator QIV. Adverse reactions were similar between the two groups, and no vaccine-related serious adverse events were reported. The study concluded that the immunogenicity of Sinovac QIV was non-inferior to the comparator QIV, and safety was comparable. [Extracted from the article]